The epitranscriptome m6A writer METTL3 promotes chemo- and radioresistance in pancreatic cancer cells

Kosuke Taketo, Masamitsu Konno, Ayumu Asai, Jun Koseki, Masayasu Toratani, Taroh Satoh, Yuichiro Doki, Masaki Mori, Hideshi Ishii, Kazuhiko Ogawa

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

N6-methyladenosine (m6A) is the most abundant epitranscriptome modification in mammalian mRNA. Recent years have seen substantial progress in m6A epitranscriptomics, indicating its crucial roles in the initiation and progression of cancer through regulation of RNA stabilities, mRNA splicing, microRNA processing and mRNA translation. However, by what means m6A is dynamically regulated or written by enzymatic components represented by methyltransferase-like 3 (METTL3) and how m6A is significant for each of the numerous genes remain unclear. We focused on METTL3 in pancreatic cancer, the prognosis of which is not satisfactory despite the development of multidisciplinary therapies. We established METTL3-knockdown pancreatic cancer cell line using short hairpin RNA. Although morphologic and proliferative changes were unaffected, METTL3-depleted cells showed higher sensitivity to anticancer reagents such as gemcitabine, 5-fluorouracil, cisplatin and irradiation. Our data suggest that METTL3 is a potent target for enhancing therapeutic efficacy in patients with pancreatic cancer. In addition, we performed cDNA expression analysis followed by gene ontology and protein-protein interaction analysis using the Database for Annotation, Visualization, and Integrated Discovery and Search Tool for the Retrieval of Interacting Genes/Proteins databases, respectively. The results demonstrate that METTL3 was associated with mitogen-activated protein kinase cascades, ubiquitin-dependent process and RNA splicing and regulation of cellular process, suggesting functional roles and targets of METTL3.

Original languageEnglish
Pages (from-to)621-629
Number of pages9
JournalInternational journal of oncology
Volume52
Issue number2
DOIs
Publication statusPublished - Feb 2018

Fingerprint

Methyltransferases
Pancreatic Neoplasms
gemcitabine
RNA Splicing
Protein Databases
Messenger RNA
Gene Ontology
Proteins
RNA Stability
Protein Biosynthesis
Ubiquitin
Mitogen-Activated Protein Kinases
MicroRNAs
Fluorouracil
Small Interfering RNA
Cisplatin
Complementary DNA
Databases
Cell Line
Therapeutics

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

The epitranscriptome m6A writer METTL3 promotes chemo- and radioresistance in pancreatic cancer cells. / Taketo, Kosuke; Konno, Masamitsu; Asai, Ayumu; Koseki, Jun; Toratani, Masayasu; Satoh, Taroh; Doki, Yuichiro; Mori, Masaki; Ishii, Hideshi; Ogawa, Kazuhiko.

In: International journal of oncology, Vol. 52, No. 2, 02.2018, p. 621-629.

Research output: Contribution to journalArticle

Taketo, K, Konno, M, Asai, A, Koseki, J, Toratani, M, Satoh, T, Doki, Y, Mori, M, Ishii, H & Ogawa, K 2018, 'The epitranscriptome m6A writer METTL3 promotes chemo- and radioresistance in pancreatic cancer cells', International journal of oncology, vol. 52, no. 2, pp. 621-629. https://doi.org/10.3892/ijo.2017.4219
Taketo, Kosuke ; Konno, Masamitsu ; Asai, Ayumu ; Koseki, Jun ; Toratani, Masayasu ; Satoh, Taroh ; Doki, Yuichiro ; Mori, Masaki ; Ishii, Hideshi ; Ogawa, Kazuhiko. / The epitranscriptome m6A writer METTL3 promotes chemo- and radioresistance in pancreatic cancer cells. In: International journal of oncology. 2018 ; Vol. 52, No. 2. pp. 621-629.
@article{39629ff53f834277bbe874faaf87227f,
title = "The epitranscriptome m6A writer METTL3 promotes chemo- and radioresistance in pancreatic cancer cells",
abstract = "N6-methyladenosine (m6A) is the most abundant epitranscriptome modification in mammalian mRNA. Recent years have seen substantial progress in m6A epitranscriptomics, indicating its crucial roles in the initiation and progression of cancer through regulation of RNA stabilities, mRNA splicing, microRNA processing and mRNA translation. However, by what means m6A is dynamically regulated or written by enzymatic components represented by methyltransferase-like 3 (METTL3) and how m6A is significant for each of the numerous genes remain unclear. We focused on METTL3 in pancreatic cancer, the prognosis of which is not satisfactory despite the development of multidisciplinary therapies. We established METTL3-knockdown pancreatic cancer cell line using short hairpin RNA. Although morphologic and proliferative changes were unaffected, METTL3-depleted cells showed higher sensitivity to anticancer reagents such as gemcitabine, 5-fluorouracil, cisplatin and irradiation. Our data suggest that METTL3 is a potent target for enhancing therapeutic efficacy in patients with pancreatic cancer. In addition, we performed cDNA expression analysis followed by gene ontology and protein-protein interaction analysis using the Database for Annotation, Visualization, and Integrated Discovery and Search Tool for the Retrieval of Interacting Genes/Proteins databases, respectively. The results demonstrate that METTL3 was associated with mitogen-activated protein kinase cascades, ubiquitin-dependent process and RNA splicing and regulation of cellular process, suggesting functional roles and targets of METTL3.",
author = "Kosuke Taketo and Masamitsu Konno and Ayumu Asai and Jun Koseki and Masayasu Toratani and Taroh Satoh and Yuichiro Doki and Masaki Mori and Hideshi Ishii and Kazuhiko Ogawa",
year = "2018",
month = "2",
doi = "10.3892/ijo.2017.4219",
language = "English",
volume = "52",
pages = "621--629",
journal = "International Journal of Oncology",
issn = "1019-6439",
publisher = "Spandidos Publications",
number = "2",

}

TY - JOUR

T1 - The epitranscriptome m6A writer METTL3 promotes chemo- and radioresistance in pancreatic cancer cells

AU - Taketo, Kosuke

AU - Konno, Masamitsu

AU - Asai, Ayumu

AU - Koseki, Jun

AU - Toratani, Masayasu

AU - Satoh, Taroh

AU - Doki, Yuichiro

AU - Mori, Masaki

AU - Ishii, Hideshi

AU - Ogawa, Kazuhiko

PY - 2018/2

Y1 - 2018/2

N2 - N6-methyladenosine (m6A) is the most abundant epitranscriptome modification in mammalian mRNA. Recent years have seen substantial progress in m6A epitranscriptomics, indicating its crucial roles in the initiation and progression of cancer through regulation of RNA stabilities, mRNA splicing, microRNA processing and mRNA translation. However, by what means m6A is dynamically regulated or written by enzymatic components represented by methyltransferase-like 3 (METTL3) and how m6A is significant for each of the numerous genes remain unclear. We focused on METTL3 in pancreatic cancer, the prognosis of which is not satisfactory despite the development of multidisciplinary therapies. We established METTL3-knockdown pancreatic cancer cell line using short hairpin RNA. Although morphologic and proliferative changes were unaffected, METTL3-depleted cells showed higher sensitivity to anticancer reagents such as gemcitabine, 5-fluorouracil, cisplatin and irradiation. Our data suggest that METTL3 is a potent target for enhancing therapeutic efficacy in patients with pancreatic cancer. In addition, we performed cDNA expression analysis followed by gene ontology and protein-protein interaction analysis using the Database for Annotation, Visualization, and Integrated Discovery and Search Tool for the Retrieval of Interacting Genes/Proteins databases, respectively. The results demonstrate that METTL3 was associated with mitogen-activated protein kinase cascades, ubiquitin-dependent process and RNA splicing and regulation of cellular process, suggesting functional roles and targets of METTL3.

AB - N6-methyladenosine (m6A) is the most abundant epitranscriptome modification in mammalian mRNA. Recent years have seen substantial progress in m6A epitranscriptomics, indicating its crucial roles in the initiation and progression of cancer through regulation of RNA stabilities, mRNA splicing, microRNA processing and mRNA translation. However, by what means m6A is dynamically regulated or written by enzymatic components represented by methyltransferase-like 3 (METTL3) and how m6A is significant for each of the numerous genes remain unclear. We focused on METTL3 in pancreatic cancer, the prognosis of which is not satisfactory despite the development of multidisciplinary therapies. We established METTL3-knockdown pancreatic cancer cell line using short hairpin RNA. Although morphologic and proliferative changes were unaffected, METTL3-depleted cells showed higher sensitivity to anticancer reagents such as gemcitabine, 5-fluorouracil, cisplatin and irradiation. Our data suggest that METTL3 is a potent target for enhancing therapeutic efficacy in patients with pancreatic cancer. In addition, we performed cDNA expression analysis followed by gene ontology and protein-protein interaction analysis using the Database for Annotation, Visualization, and Integrated Discovery and Search Tool for the Retrieval of Interacting Genes/Proteins databases, respectively. The results demonstrate that METTL3 was associated with mitogen-activated protein kinase cascades, ubiquitin-dependent process and RNA splicing and regulation of cellular process, suggesting functional roles and targets of METTL3.

UR - http://www.scopus.com/inward/record.url?scp=85040347740&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85040347740&partnerID=8YFLogxK

U2 - 10.3892/ijo.2017.4219

DO - 10.3892/ijo.2017.4219

M3 - Article

C2 - 29345285

AN - SCOPUS:85040347740

VL - 52

SP - 621

EP - 629

JO - International Journal of Oncology

JF - International Journal of Oncology

SN - 1019-6439

IS - 2

ER -